At the news
? NEUTRALIMPACT 4/10 DEFA14A filed Sep 30, 2026 at 06:01 ET
BioLife Solutions filed supplemental proxy disclosures in connection with its pending acquisition by Repligen Corporation, providing additional detail on executive retention and severance arrangements. The filing also discloses two shareholder lawsuits challenging the merger disclosures, though management denies the allegations and intends to defend vigorously. The special stockholder vote on the merger is scheduled for October 5, 2026.
- Repligen will acquire BioLife for $11.25 cash and 0.1442 shares of Repligen common stock per BioLife share.
- Special stockholder meeting to vote on the merger is scheduled for October 5, 2026 at 9:00 a.m. ET.
- Two shareholder lawsuits filed in New York state court on September 10, 2026 allege inadequate disclosures in the proxy statement.
- BioLife denies the allegations and intends to vigorously defend against the lawsuits.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access